Literature DB >> 8040766

Correlation of cognitive, neurologic, and ovarian outcome with the Q188R mutation of the galactose-1-phosphate uridyltransferase gene.

F R Kaufman1, J K Reichardt, W G Ng, Y K Xu, F R Manis, C McBride-Chang, J A Wolff.   

Abstract

This study was conducted to determine whether there is a genotype/phenotype correlation between aspects of cognitive, neurologic, and ovarian outcome in patients with galactosemia and the Q188R mutation of the galactose-1-phosphate uridyltransferase gene. The results showed that the Q188R mutation was found in 72% of alleles: 38 patients were homozygous and 21 were heterozygous for Q188R; eight patients did not have the mutation. The mean Broad Cognitive score for the group homozygous for Q188R was 75 (SD = 16), which was not statistically different from the outcome for the heterozygous group (mean score, 67; SD = 25) or the negative group (mean score, 88; SD = 21). Tremor, ataxia, and dysmetria were found in 12 subjects, and there was no association with Q188R status. Similarly, there was no association of this mutation with the development of primary amenorrhea (8 subjects) versus secondary amenorrhea (found in 14 women). Our findings suggests that the variability of outcome for patients with classic galactosemia cannot be explained by Q188R status alone, at least with regard to cognitive functioning, presence of neurologic symptoms, and timing of the onset of ovarian failure.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8040766     DOI: 10.1016/s0022-3476(94)70197-0

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  18 in total

1.  A controversial expert witness.

Authors: 
Journal:  Arch Dis Child       Date:  2000-09       Impact factor: 3.791

2.  Komrower Lecture. Galactosaemia today: the enigma and the challenge.

Authors:  S Segal
Journal:  J Inherit Metab Dis       Date:  1998-08       Impact factor: 4.982

3.  Cross-sectional analysis of speech and cognitive performance in 32 patients with classic galactosemia.

Authors:  Björn Hoffmann; Udo Wendel; Susanne Schweitzer-Krantz
Journal:  J Inherit Metab Dis       Date:  2011-02-24       Impact factor: 4.982

4.  Galactosaemia: relationship of IQ to biochemical control and genotype.

Authors:  M A Cleary; L E Heptinstall; J E Wraith; J H Walter
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

5.  Three missense mutations in the galactose-1-phosphate uridyltransferase gene of three families with mild galactosaemia.

Authors:  Y S Shin; B S Gathof; T Podskarbi; M Sommer; R Giugliani; U Gresser
Journal:  Eur J Pediatr       Date:  1996-05       Impact factor: 3.183

6.  The relationship of genotype to cognitive outcome in galactosaemia.

Authors:  J P Shield; E J Wadsworth; A MacDonald; A Stephenson; L Tyfield; J B Holton; N Marlow
Journal:  Arch Dis Child       Date:  2000-09       Impact factor: 3.791

7.  Cryptic residual GALT activity is a potential modifier of scholastic outcome in school age children with classic galactosemia.

Authors:  Emily L Ryan; Mary Ellen Lynch; Elles Taddeo; Tyler J Gleason; Michael P Epstein; Judith L Fridovich-Keil
Journal:  J Inherit Metab Dis       Date:  2013-01-15       Impact factor: 4.982

8.  Characterization of two stop codon mutations in the galactose-1-phosphate uridyltransferase gene of three male galactosemic patients with severe clinical manifestation.

Authors:  B S Gathof; M Sommer; T Podskarbi; J Reichardt; A Braun; U Gresser; Y S Shin
Journal:  Hum Genet       Date:  1995-12       Impact factor: 4.132

9.  Two adult galactosaemia females with normal ovarian function and identical GALT mutations (Q188R/R333G).

Authors:  W G Ng; Y K Xu; L J Wong; F R Kaufman; N R M Buist; G N Donnell
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

10.  Biochemical and molecular studies of 132 patients with galactosemia.

Authors:  W G Ng; Y K Xu; F R Kaufman; G N Donnell; J Wolff; R J Allen; S Koritala; J K Reichardt
Journal:  Hum Genet       Date:  1994-10       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.